The CENOBITE study will be conducted as a multi-center trial involving X leading centers from the Critical Care EEG Monitoring Consortium (CCEMRC). A total of 10 patients will be recruited over a period of one year, with each patient undergoing monitored treatment regimen. Each site will obtain its own approval from their institutional review board. Data will be shared through the MGB REDCap; raw EEG files will be shared through the MGB Dropbox and analyzed at the BWH. Monitoring for the development of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, a potential adverse reaction, will be a key aspect of the study. Regular assessments, including RegiSCAR scoring (a validated scoring system for DREeSS5), daily serum cenobamate level measurements, and comprehensive lab tests, will be conducted to ensure patient safety and the effective management of any adverse reactions such as DRESS syndrome.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14) * Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days. * Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7
Brigham and Women's Hospital
Boston, Massachusetts, United States
Target level
Percentage of patients reaching target level of 10±2 ug/mL after load.
Time frame: 6 hours after bolus
Maintenance level
Percentage of patients maintaining daily therapeutic level of 10±2 ug/mL
Time frame: Up to 14 days
Seizure cessation
Percentage of seizure cessation within 24 hours of reaching the target level.
Time frame: Up to 14 days
Seizure burden change
Percentage change in seizure burden over 24 hours
Time frame: Up to 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.